Hypertension
Conditions
Interventions
The patients with hypertension under treatment with valsartan 80 mg/day or amlodipine 5 mg/day (a single-pill fixed-dose combination) are enrolled. The patients receive a single-pill fixed-dose combin
Sponsors
Department of Cardiology,Fukuoka University School of Medicine.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with essential hypertension who received a single-pill fixed dose combination of valsartan and amlodipine at least for 8 weeks. 2.Age is 20 years old or more. 3.Patients who gave their informed consent to participate for the present study.
Exclusion criteria
Exclusion criteria: 1.Severe liver dysfunction. 2.Severe renal dysfunction. 3.Pregnancy or lactation in women. 4.Patients with a history of allergy to any component of the study medications. 5.Patients corresponding to the contraindication of study medications. 6.Ineligible patients according to the judgment by physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Depressor effects at office blood pressure and the percentage of patients who reach the target office blood pressure. 2.Depressor effects at home blood pressure and the percentage of patients who reach the target home blood pressure. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Percentage of adverse effects. 2.Changes in biochemical parameters in blood and urine. | — |
Countries
Japan
Contacts
Public ContactShin-ichiro Miura
Fukuoka University School of Medicine Department of Cardiology
Outcome results
None listed